Stifel raised the firm’s price target on Freeline to $4 from $3 and keeps a Hold rating on the shares. The upcoming readout on FLT201 could help build on the company’s increasing experience with AAVS3 gene delivery with meaningful learnings adopted from prior endeavors, but the firm anticipates continued pressure on the stock given the given the depth and breadth of data expected from Cohort 1 vis-a-vis the cash runway, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on FRLN:
- Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
- Freeline expects initial clinical data from GALILEO-1 trial in Q3
- Freeline expects cash to fund operations into 2Q24
- Freeline reports 1H EPS (23c) vs. (95c) last year
- Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
